ResultsIQ

ResultsIQ › Latest results › Senores Pharmaceuticals Limited

Senores Pharmaceuticals Limited Q2 FY27 results deck summary

NSE: SENORES · BSE: 544319

Results deck of 29 Oct 2026, summarised by AI from the filing.

Q2 FY27 revenue ₹192.3 cr (+24.9%) and EBITDA ₹57.7 cr (+38.3%), with H2 expected to be considerably better than H1 on anticipated launches.

Key takeaways

  1. Q2 revenue Q2 FY27 revenue was ₹192.3 cr (Q2 FY26: ₹153.9 cr, +24.9%) and EBITDA ₹57.7 cr (Q2 FY26: ₹41.7 cr, +38.3%).
  2. H2 outlook H2 is expected to be considerably better than H1 owing to anticipated launches, with Zoraya and Amerisyn contributing from H2 FY27.
  3. Margin expansion H1 FY27 EBITDA margin was 29.9% (H1 FY26: 24.6%), up 530 bps, and Q2 FY27 margin 30.0% (Q2 FY26: 27.1%).
  4. Regulated Markets Regulated Markets revenue grew 34.3% to ₹264.5 cr in H1FY27 at ~42% EBITDA margin, 71% of total revenue.
  5. Investment drag EBITDA growth came despite investments in Apnar, Zoraya and Amerisyn, whose revenues are to ramp up over the next 12 months.

Original filing on BSE

Senores Pharmaceuticals Limited Q1 FY27 results

As filed: Revenue ₹180 cr (+31% year on year), EBITDA ₹53.8 cr (+58% year on year), PAT ₹30.5 cr (+45% year on year), EBITDA margin 29.8% (+519 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹175 cr (+54% year on year), EBITDA ₹47.5 cr (+150% year on year), PAT ₹36.7 cr (+104% year on year), EBITDA margin 27.1% (+1,000 bps). Score 92 of 100, Above trend. EBITDA margin rose 1000 bps year on year. Other income 37% of PBT. Not enough history for a trend yet: scored on growth alone. Share price after the results: +32.5% in 29 days (Nifty 500: +1.0%).
  • Q3 FY26: Revenue ₹175 cr (+69% year on year), EBITDA ₹54.0 cr (+116% year on year), PAT ₹33.6 cr (+110% year on year), EBITDA margin 30.9% (+666 bps). Score 100 of 100, Above trend. EBITDA margin rose 666 bps year on year. Not enough history for a trend yet: scored on growth alone. Share price after the results: +1.1% in 30 days (Nifty 500: −0.3%).
  • Q2 FY26: Revenue ₹162 cr, EBITDA ₹50.0 cr, PAT ₹30.0 cr, EBITDA margin 30.9%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹162 cr). Scored once a year-earlier consolidated quarter exists. Share price after the results: +1.3% in 29 days (Nifty 500: +0.7%).
  • Q1 FY26: Revenue ₹138 cr, EBITDA ₹34.0 cr, PAT ₹21.0 cr, EBITDA margin 24.6%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹138 cr). Scored once a year-earlier consolidated quarter exists. Share price after the results: +18.9% in 30 days (Nifty 500: −1.9%).
  • Q4 FY25: Revenue ₹114 cr, EBITDA ₹19.0 cr, PAT ₹18.0 cr, EBITDA margin 16.7%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹114 cr). Scored once a year-earlier consolidated quarter exists. Share price after the results: +7.3% in 30 days (Nifty 500: +0.2%).
  • Q3 FY25: Revenue ₹103 cr, EBITDA ₹25.0 cr, PAT ₹16.0 cr, EBITDA margin 24.3%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹103 cr). Scored once a year-earlier consolidated quarter exists.

Past price moves after results do not indicate future moves. Not a recommendation.

Senores Pharmaceuticals Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.